The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.


All material subject to strictly enforced copyright laws. © 2021 Euromoney, a part of the Euromoney Institutional Investor PLC.
Capital Markets

Montgomery into equities

Montgomery & Co is known for its M&A advisory services. Now, it's pushing into equity research, institutional sales and trading. It will offer specialist research in key areas for growth companies: medical devices, biotechnology, speciality pharmaceuticals, wireless technology, digital media technology and semiconductors.

Montgomery & Co has been known for some years for its M&A advisory services. Now, after pondering for a couple of years what it could do in equities, the US west coast boutique player is pushing into equity research, institutional sales and trading. Although the firm’s headquarters are in Santa Monica, the equities office was set up in July in San Francisco.

Montgomery will focus on small and mid-size companies in the technology, software and biomedical sectors. It will offer specialist research in key areas for growth companies: medical devices, biotechnology, speciality pharmaceuticals, wireless technology, digital media technology and semiconductors.

Wade King heads the research effort, having joined from Wells Fargo in March this year, where he was managing director of healthcare research. But it’s not just planning to offer research on small and mid-cap companies that are now often neglected by sell-side analysts at the bulge-bracket banks. It plans to do IPOs, follow-ons and non-deal roadshows, among other things, and offer trading capabilities.

“We’ve got to be smart,” says John Roediger, who is managing director and head of institutional sales and trading at Montgomery’s new equities practice. “First we’ve got to establish the high-quality relationships, then we’ve got to focus on institutional growth accounts.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.

SUBSCRIBE ONLINE TODAY

Unlimited access to Euromoney.com and Asiamoney.com

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually

FREE 7 DAY TRIAL

Unlimited access to Euromoney.com and Asiamoney.com, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors

LOGIN NOW

Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree